Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Paracelsian Inc (PRLN) -- Ignore unavailable to you. Want to Upgrade?

To: Judy Muldawer who wrote (3999)	11/29/1998 7:56:00 AM
From: John H. Farro	Respond to of 4342

Judy, I think that, rightly or wrongly, the market is in a "show me" mood as far as PRLN is concerned. PRLN is on the verge of launching its BioFit program, but until it announces that it has actually signed up some major distributors and BioFit products are ready to go to market, I doubt we will get much of a pop. Why is this? It is unfair to current management but PRLN is burdened with a past of not delivering. Who can forget John Babish in Feb 1997 saying at the Smith Barney conference that PRLN would hire a prominent AIDS doctor by April to help launch AndroVir in May. Babish quit about a month later and we were told that product launch would be delayed until September. No AIDS doctor was ever hired and the product launch never happened. I don't think its fair that current management should have to suffer for past management's mistakes, but you can't fight the market. I think the stockholders are still paying for the Babish/Rhodes' legacy. The stock took a major hit after the last press release. I think the key sentence was this: "As part of the program, Paracelsian and R.P. Scherer are working together to develop products (including Echinacea, Saw Palmetto, St. John's Wort, Ginseng, and Ginkgo biloba) to be offered through a variety of major herbal marketers in early 1999. " The market looked at this sentence and did its best Peggy Lee imitation by saying "Is that all there is?" At this point the market will not be satisfied by anything less than concrete deals with new distributors. Even that might not be enough. The market might actually want to see products on the shelves before popping the stock price. Of course, there are other possibilities that could increase the stock price. I think we should probably see some results from the SRI testing sometime in December. If they are positive then that could cause the price to shoot up. Or if PRLN pulled off a major deal to market the Ah ImmunoAssay then that could increase the price as well. It has been a while since there has been some real news. PRLN's price has always drifted down during such periods. Let's hope we get some good news soon. Robin P.S. I got post #4000. I think it's going to be easier to get the important post numbers now that Rick Costantino is no longer competing for them.